FDA launches online portal to facilitate plasma donation from recovered COVID-19 patients

The FDA released an online portal that allows recovered COVID-19 patients to access resources on plasma donation to help others fight off the infection.

Advertisement

The website helps recovered COVID-19 patients connect with local blood and plasma collection centers to determine their eligibility to donate as well as potentially schedule an appointment.

Convalescent plasma is in the blood of patients who have recovered from COVID-19; patients with the novel coronavirus disease develop antibodies in their blood against the virus. The convalescent plasma donated by these patients may help some other patients recover from COVID-19, as well.

The portal also provides information for people interested in participating in clinical trials or submitting patient emergency investigational new drug applications. Users can also find participation information about the government’s national effort to collect and distribute convalescent plasma to U.S. patients in need. Rochester, Minn.-based Mayo Clinic is leading the National Expanded Access Treatment Protocol, which aims to connect COVID-19 patients who may benefit from receiving plasma with donations.

More articles on health IT:
10 cybersecurity tips for clinicians working from home during the pandemic 
The difference-makers during the surge: 6 CIOs on top priorities and key advice amid COVID-19
Apple Maps asks coronavirus testing sites to submit their locations

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Health IT

Advertisement

Comments are closed.